Selective interstitial doxorubicin for recurrent glioblastoma

Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood‐brain barrier and to assure a minimal dose concentration of the chemotherapy agent. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Matcovschii, Valerii, Lisii, Dan, Gudumac, Valentin, Dorosenco, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935603/
https://www.ncbi.nlm.nih.gov/pubmed/31893093
http://dx.doi.org/10.1002/ccr3.2546
_version_ 1783483600715382784
author Matcovschii, Valerii
Lisii, Dan
Gudumac, Valentin
Dorosenco, Stanislav
author_facet Matcovschii, Valerii
Lisii, Dan
Gudumac, Valentin
Dorosenco, Stanislav
author_sort Matcovschii, Valerii
collection PubMed
description Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood‐brain barrier and to assure a minimal dose concentration of the chemotherapy agent. Doxorubicin might be devoid of neurotoxic effects and still efficient on remaining far‐infiltrated tumor cells.
format Online
Article
Text
id pubmed-6935603
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69356032019-12-31 Selective interstitial doxorubicin for recurrent glioblastoma Matcovschii, Valerii Lisii, Dan Gudumac, Valentin Dorosenco, Stanislav Clin Case Rep Case Reports Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood‐brain barrier and to assure a minimal dose concentration of the chemotherapy agent. Doxorubicin might be devoid of neurotoxic effects and still efficient on remaining far‐infiltrated tumor cells. John Wiley and Sons Inc. 2019-11-19 /pmc/articles/PMC6935603/ /pubmed/31893093 http://dx.doi.org/10.1002/ccr3.2546 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Matcovschii, Valerii
Lisii, Dan
Gudumac, Valentin
Dorosenco, Stanislav
Selective interstitial doxorubicin for recurrent glioblastoma
title Selective interstitial doxorubicin for recurrent glioblastoma
title_full Selective interstitial doxorubicin for recurrent glioblastoma
title_fullStr Selective interstitial doxorubicin for recurrent glioblastoma
title_full_unstemmed Selective interstitial doxorubicin for recurrent glioblastoma
title_short Selective interstitial doxorubicin for recurrent glioblastoma
title_sort selective interstitial doxorubicin for recurrent glioblastoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935603/
https://www.ncbi.nlm.nih.gov/pubmed/31893093
http://dx.doi.org/10.1002/ccr3.2546
work_keys_str_mv AT matcovschiivalerii selectiveinterstitialdoxorubicinforrecurrentglioblastoma
AT lisiidan selectiveinterstitialdoxorubicinforrecurrentglioblastoma
AT gudumacvalentin selectiveinterstitialdoxorubicinforrecurrentglioblastoma
AT dorosencostanislav selectiveinterstitialdoxorubicinforrecurrentglioblastoma

Ejemplares similares